Decreased severity of experimental autoimmune arthritis in peptidylarginine deiminase type 4 knockout mice by Akari Suzuki et al.
RESEARCH ARTICLE Open Access
Decreased severity of experimental
autoimmune arthritis in peptidylarginine
deiminase type 4 knockout mice
Akari Suzuki1*, Yuta Kochi1, Hirofumi Shoda2, Yu Seri3, Keishi Fujio3, Tetsuji Sawada4, Ryo Yamada1 and
Kazuhiko Yamamoto1,3
Abstract
Background: Peptidylarginine deiminase type 4 (PADI4) has been identified as a susceptibility gene for rheumatoid
arthritis (RA) by genome-wide association studies. PADI4 is highly expressed in the bone marrow, macrophages,
neutrophils, and monocytes. Peptidyl citrulline is an interesting molecule in RA because it is a target antigen for
anti-citrullinated peptide antibodies, and only PADs (translated proteins from PADI genes) can provide peptidyl
citrulline via the modification of protein substrates. The aim of this study was to evaluate the importance of the
PADI4 gene in the progression of RA.
Methods: We generated Padi4 knockout (Padi4−/−) DBA1J mice. The Padi4−/− DBA1J and wild-type mice were
immunized with bovine type II collagen (CII) to develop collagen-induced arthritis (CIA). The expression of various
inflammatory cytokines and Padi genes in immune cells was detected by the real-time TaqMan assay. Cytokine
concentrations in sera were measured by enzyme-linked immunosorbent assays. Localization of the PAD4 and
PAD2 proteins was indicated by immunohistochemistry.
Results: We demonstrated that the clinical disease score was significantly decreased in the Padi4−/− mice and Padi4
expression was induced by CII immunization. In the Padi4−/− mice, serum anti-type II collagen (CII) immunoglobulin M
(IgM), IgG, and inflammatory cytokine levels were significantly decreased compared with those in the wild-type mice.
Padi2 expression was induced in the immune cells of the Padi4−/− mice as a compensation for the defect in Padi4.
Conclusions: Padi4 affected disease severity in the CIA mice and was involved in the enhancement of the
collagen-initiated inflammatory responses.
Keywords: Peptidylarginine deiminase type 4, Rheumatoid arthritis, Collagen-induced arthritis mice, TNF-α,
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Background
Autoimmune diseases are caused by multiple factors, in-
cluding genes and environmental factors. Rheumatoid
arthritis (RA) is one of the most common systemic auto-
immune diseases in humans, with a worldwide preva-
lence of approximately 1 % [1, 2]. It is characterized by
inflammation of the synovial tissues and the formation
of a rheumatoid pannus, which is capable of eroding the
adjacent cartilage and bone and causing subsequent joint
destruction.
Many non-HLA loci have been identified as RA sus-
ceptibility genes in genome-wide association studies
(GWASs). We previously identified peptidylarginine dei-
minase type 4 (PADI4) as an RA susceptibility gene in a
large-scale, case-control association study using a gene-
based GWAS method [1]. We identified single nucleo-
tide polymorphisms (SNPs) associated with the develop-
ment of RA in the coding region of PADI4, and these
RA-causal SNPs were associated with allelic imbalances
in gene expression, with pathological relevance. PADI4
susceptibility to RA was initially observed only in Asian
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populations [3–7]. However, PADI4 has also been associ-
ated with RA in mega-GWASs involving multiple ethnic
groups [8–11]. Therefore, PADI4 has been recognized as
a common genetic risk factor for RA.
Although some of the risk genes identified by GWASs
are shared among autoimmune diseases, PADI4 has
been associated only with RA [12, 13]. The reason for
this specificity may be that PADs have catalytic activity
in the conversion of peptidylarginine to peptidyl citrul-
line, and citrulline-containing epitopes are the most
specific targets of RA-specific autoantibodies, well
known as anti-citrullinated protein antibodies (ACPA),
e.g., cyclic citrullinated peptide (CCP) antibody. The
strongest genetic association in RA was observed in the
HLA region on chromosome 6p21. This region extends
over 3.6 Mb, including the major histocompatibility
complex (MHC)-class I, II, and III molecules, and con-
tains many genes with immunoregulatory functions. Pre-
viously, it was reported that HLA-DRB1 SE alleles were
associated with ACPA-positive RA but not with ACPA-
negative RA [14, 15]. Therefore, it appears that PADI
genes functionally interact with the HLA-DRB1 SE allele
and are related to the production of ACPA. Ethnic het-
erogeneity in the genetic risk factors for RA, including
genetic variations and effect sizes such as those for the
HLA-DRB1 alleles, protein tyrosine phosphatase, non-
receptor type 22 (PTPN22) alleles, and PADI4 alleles,
has been noted in different populations. The difference
in the contribution of PADI4 to RA between Asians and
Europeans may be caused by the difference in the preva-
lence of smoking as well as other genetic and environ-
mental factors among these ethnic groups [16–18]. The
interactions among smoking history, PADI4 polymor-
phisms, and HLA-DRB1 SE have been investigated in
some populations [16, 17, 19]. The reasons for the differ-
ent effect sizes of the other susceptibility genes remain
unclear; moreover, little or nothing is known about the
manner in which these genetic risks pathologically affect
the mechanisms underlying RA development. PAD
expression and activity are increased in the lung of a
smoker and also seropositivity, e.g., RF associated with
smoking status [20]. HLA-DRB1 SE alleles conferred the
highest risk of developing anti-CCP antibodies [18] and
PADI4 and HLA-DRB1 SE had also associated with joint
destruction and anti-CCP positivity [21]. However, dir-
ectly functional association between PADI4 and HLA-
DRB1 SE has been not shown.
Many citrullinated proteins/peptides have been re-
ported, such as filaggrin, K1 keratin, and fibrinogen
[22–30]. Dermal citrullination seems to be the most
thoroughly investigated. Originally, the antigen of the
circulated citrullinated peptide antibody was based on
a citrullinated filaggrin peptide. These citrullinated pro-
teins are only provided during post-translation using
PADIs because citrulline is a noncoding amino acid. Fur-
thermore, biological events such as inflammation, apop-
tosis, and aging increase post-translational citrullination
[31–33]. Citrullinated proteins are candidate autoantigens;
however, their pathophysiological functions in RA devel-
opment remain unknown.
The function of PAD4, which is encoded by the PADI4
gene, plays a role in the intranuclear citrullination of his-
tones and regulation of gene expression [34, 35]. The
citrullination of histones is apparently linked to histone
methylation and acetylation in the regulatory mechanism
of gene expression. In particular, citrullination of the his-
tone H4R3 related to the p53 pathway plays an import-
ant role in response to DNA damage in carcinogenesis
[36]. PAD4 also modified ELK1, a major transcriptional
element, and citrullinated ELK1 activated the expression
of the c-Fos oncogene [37]. Furthermore, PADI2, a
member of the PADI gene family, is not localized in the
nucleus; however, PAD2 affects gene transcription via
the citrullination of IKK-gamma [38]. These data indicate
that citrullination plays an important role in transcription.
Therefore, PADI4 is genetically and functionally important
for both RA and carcinogenesis.
As a result, the PAD4 enzyme became a candidate tar-
get for RA therapy [39]. It was reported that Cl-amidine,
which is one of the pan-PAD inhibitors, suppressed arth-
ritis induced by collagen-induced arthritis (CIA) [40].
Cl-amidine also strongly affected breast tumor progres-
sion by inhibiting PADIs [41].
To investigate the function of PADI4 in physiological
conditions and the relationship between citrullination
and RA development, we analyzed mice that lacked the
PAD4 enzyme and generated Padi4−/− DBA1J mice by
the speed congenic method. We found that PAD4 af-
fected the development and progression of CIA in an
animal model of RA. However, the incidence was not
significantly different. In addition, serum anti-Type II
collagen (CII), IgM, IgG, Il-6, and tumor necrosis factor
alpha (TNF-α) levels in the Padi4 knockout mice with
CIA were significantly decreased compared with those
in the wild-type mice with CIA.
Methods
Mice
Congenic inbred Padi4−/− C57BL/6 J (B6) back-
ground mice [36] were backcrossed with DBA1JNCrIj
(DBA1J) (>99.5 % of the DBA1J) by the speed congenic
method based on the protocol provided by Applied Bio-
systems (http://tools.invitrogen.com/content/sfs/manuals/
cms_039321.pdf). The DBA1J background was confirmed
by genotyping 269 single nucleotide polymorphisms
(SNPs) using the Invader assay. Southern blot analyses
and genotypes were confirmed by PCR analyses to
verify correct targeting and transmission of the
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ATAGC, beta-actin (Actb)_F1: CTCTATCACTGGG
CATCGAG, and Actb_R1: GCAAGCTCCGCCTAC
ACTG. We used Southern blotting and reverse
transcription-polymerase chain reaction (RT-PCR) to
determine the genomic structure and presence of the
Padi4 transcripts [36]. DBA1JNCrIj (DBA1J) mice
were purchased from Charles River Japan. All mice
were maintained under specific pathogen-free conditions.
The local ethics committee of Animal Experiments in the
RIKEN IMS approved all animal procedures.
Induction of CIA and assessment of arthritis
Male, wild-type DBA1J or Padi4−/− DBA1J mice aged
8–10 weeks were immunized on day 0 with complete
Freund’s adjuvant (CFA, Chondrex, Redmond, WA)
containing 100 μg of bovine type II collagen (Chon-
drex) in a 1:1 mixture of adjuvant and collagen. The
injections were subcutaneously administered into the
base of the tail [42]. The control mice received the
same volume of reagent without the collagen. On day
21, the mice were administered an intradermal booster in-
jection with a mixture of incomplete Freund’s adjuvant
(IFA, Chondrex) and collagen near the former injection
sites. Arthritis was assessed using the following clinical
scoring system for each limb: 0, normal; 1, redness and/or
swelling in one joint; 2, redness and/or swelling in more
than one joint; 3, redness and/or swelling in the entire
paw; and 4, deformity and/or ankylosis. The maximum
score was 16 per mouse.
Detection of anti-CII antibodies
Serum samples were obtained from all experimental ani-
mals prior to immunization and on days 21, 28, 35, 42,
49, and 56 after the first immunization. Anti-CII anti-
bodies were detected by ELISA at a dilution of 1:8000
[43]. Polystyrene 96-well microtiter plates (AGC Techno
Glass, Tokyo, Japan) were coated with 10 μg/mL of bo-
vine type II collagen in 5-mM acetic acid overnight at
4 °C. The plates were then washed, and nonspecific
binding was blocked using the blocking buffer (10 % al-
bumin, bovine, F-V, pH 5.2/T-PBS, pH 7.5) for 2 h at
room temperature (RT). Following extensive washing, all
subsequent dilutions were made in sample dilution buf-
fer (0.5 % albumin, bovine in T-PBS) for 2 h at RT. The
plates were washed and incubated with anti-mouse IgG
(Fab)2 (1:2000, Invitrogen, Carlsbad, CA), anti-mouse
IgM (Fab)2 HRP-conjugated (1:5000, MBL, Tokyo, Japan),
anti-mouse IgG1 (1:2000, Invitrogen), anti-mouse IgG2a
(1:2000, Invitrogen), anti-mouse IgG2b (Invitrogen), and
anti-mouse IgG3 antibodies, respectively, for 1 h at RT.
After washing, the binding of anti-CII antibodies was re-
vealed by color development with OPD (Sigma-Aldrich,
St. Louis, MO). The plates were then read on a microplate
reader (Bio-rad, Hercules, CA) at a wavelength of 450 nm.
Pooled polyclonal mouse serum with a known anti-CII
antibody was included in each test plate and used as a
positive control and standard.
Isolation of cells from spleen
The DBA1J mice splenocytes were washed with MACS
wash buffer (0.5 % ovine serum albumin, 2-mM ethyl-
enediaminetetraacetic acid in PBS) before resuspension
at 1 × 108 cells/mL for magnetic separation. For the iso-
lation of granulocytes, dendritic cells, T-cells, B-cells,
and macrophages, microbeads or biotin conjugated with
anti-Gr-1, anti-MHC-class II, anti-CD5, anti-CD45R,
and anti-CD11b antibodies and a magnetic column sep-
aration system (Miltenyi Biotech, Bergisch Gladbach,
Germany) were used according to the manufacturer’s in-
structions. Purified cells were used for real-time Taqman
expression analysis and microarray analysis. For the cul-
ture of macrophages and granulocytes, isolated CD11b-
positive cells and Gr-1-positive cells were used for the
cytokine assay after lipopolysaccharide stimulation.
Bone marrow macrophage (BMM) cultures
BMMs were obtained as previously described [44, 45].
Briefly, femurs from the wild-type and Padi4−/− mice were
flushed with 2 mL of Dulbecco’s modified Eagle’s medium
(DMEM, Sigma) using a 26-gauge needle. The bone mar-
row plugs were centrifuged and resuspended in ice-cold
complete media (DMEM, 10 % fetal bovine serum, 1 %
penicillin streptomycin, 1 % glutamine, and 0.5-uM β-
mercaptoethanol). Precursor cells were generated by cul-
ture in the presence of 1-nM interleukin (IL)-3 (Miltenyi
Biotech) and 0.44-nM macrophage colony-stimulating fac-
tor (Miltenyi Biotech) for 24 h at 37 °C. Then, the cells
were differentiated into adherent macrophages by 3 days
of culture without IL-3 in complete media. The cultured
BMMs were used for RNA isolation.
RNA isolation and real-time TaqMan RT-PCR analysis for
gene expression
RNA was extracted from isolated cells using an RNAeasy
mini kit (QIAGEN, Venlo Park, The Netherlands), and
each RNA sample was treated with DNaseI (QIAGEN)
according to the manufacturer’s instructions. The total
RNA was reverse-transcribed to cDNA using a high-
capacity cDNA reverse transcription kit (Life Technologies
Inc., Carlsbad, CA) in a 96-well format. The housekeeping
gene mouse GAPD was chosen as an endogenous control
for the normalization of expression data against each gene.
All PCR primers and TaqMan probes were designed and
purchased from Life Technologies according to the
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company’s protocols. Briefly, the real-time PCR reaction
was performed at 95 °C for 10 min, followed by 40 cycles of
template denaturation at 95 °C for 15 s, with an annealing
temperature of 60 °C for 1 min. The relative transcription
levels of the individual target genes were normalized using
the internal control. All data were analyzed using PE
Applied Systems sequence Detector 2.2 software
(Applied Biosystems, Carlsbad, CA). The comparative
threshold cycle method was used to quantify data.
The results represent the expression level of the tar-
get gene relative to that of GAPD by defining ΔΔCt.
ELISA for cytokines
Cytokine levels in the sera and supernatant of cell cul-
tures were measured using the Ready-SET-GO ELISA
set for TNF-α, IL-1β, and granulocyte-macrophage
colony-stimulating factor (GM-CSF) (eBioscience, San
Diego, CA) in accordance with the manufacturer’s in-
structions. Briefly, polystyrene 96-well microtiter plates
(AGC Techno Glass) were coated with capture antibody,
and blocking reactions were performed after washing
the plates. Then, the diluted and standard samples were
added to each well. After detection of the antibody reac-
tion, TMB solution as a substrate was incubated in each
well, and the reaction was stopped using 10 % H2SO4.
Detection limits were 8–1000 pg/mL for TNF-α and Il-
1β ELISA and 4–500 pg/mL for IL-6 and GM-CSF
ELISA.
Histological staining
Paraffin-embedded sections of mouse knee joints and
spleens were provided by Genostaff (Tokyo, Japan).
Briefly, the spleens were isolated and fixed in phosphate-
buffered 4 % paraformaldehyde and embedded in paraf-
fin wax (Wako, Tokyo, Japan). Whole knee joints were
collected from the sacrificed mice and fixed, decalcified,
embedded in paraffin, sectioned, and subjected to histo-
logical analysis. The tissue sections (6 μm) were heated
at 95 °C for 10 min in a target retrieval solution (Dako,
Glostup, Denmark) for antigen recovery. Then, the
sections were incubated with 3 % H2O2 in methanol for
inactivation of the endogenous peroxidase at RT for
30 min. The sections were washed with PBS buffer and
incubated with primary antibodies. The immunostained
sections were processed using the VECTASTAINABC
kit and VECTOR M.O.M Immunodetection kit (Vector
Labs, Burlingame, CA). Rabbit anti- CCP (1:1000, Abbiotec,
San Diego, CA), rabbit anti-mouse PAD4 (1:1000, Novus
Biologicals, Littleton, CO), and mouse anti-citrullinated fi-
brinogen antibodies (1:1000, ModiQuest, Noord-Brabant,
The Netherlands) were used as primary antibodies. The im-
munoreactive signals were visualized using the DBA sub-
strate (Vector Labs), which stains the target protein brown.
Hematoxylin (Wako) was used for counterstaining.
For immunofluorescence double staining, rat anti-
mouse CD3-conjugated Alexa Fluor® 647 (1:25, AbD ser-
otec, Hercules, CA), rat anti-mouse CD56-conjugated
Alexa Fluor® 647 (1:75, Oncogene Research Products,
San Diego, CA), rat anti-mouse CD45R (anti-B220)-con-
jugated Cy5 (1:200, Cell Marque, Rocklin, CA), rat anti-
mouse F4/80 (1:200, eBioscience), and rat anti-mouse
Ly6/G (1:100, BD, Franklin Lakes, NJ) labeled with Alexa
Fluor® 647 were used as the primary antibodies. PAD4
(1:25) and PAD2 (1:25, Proteintech, Chicago, IL) were
detected using secondary antibodies labeled with Alexa
Fluor® 546. To eliminate nonspecific staining caused by
Fc receptor staining of the lymphoid and hematopoietic
cells, an Fc receptor blocker (Innovex Biosciences;
Richmond, CA) was used. For counterstaining, 4’, 6-
diamidino-2-phenylindole Vectashield (Vector Labs)
was used. For negative controls, Alexa Fluor 647 goat
anti-rat IgG (H + L) conjugate and Alexa Fluor 546
goat anti-rabbit IgG (H + L) conjugate (Invitrogen) were
used. Immunofluorescence signals were examined using
an Olympus photomicroscope (Tokyo, Japan). Informed
consent was obtained from each subject and the study
was performed in compliance with the ethical guidelines
of the RIKEN.
Statistical analysis
All statistical analyses were performed using Excel
(Microsoft, Redmond, WA).
Results
CIA development in the Padi4 knockout mice
The Padi4−/− mutant mice were created as previously
described [36]; we confirmed the genomic construct by
Southern blotting and the absence of Padi4 expression
in the knockout mice by RT-PCR (Additional file 1). The
knockout animals were back-crossed to the DBA1J
mice until they contained >99.5 % of the DBA1J gen-
ome. Histological analysis of the immune tissues by
hematoxylin–eosin staining indicated that there was
no difference; however, a slight difference among the
genotypes was observed in the skin keratin layer
(Additional file 1E). The life span of Padi4KO mice
was comparable to wild-type mice, and that those
mice did not develop spontaneous disease.
CIA was significantly less severe in the Padi4−/− mice
than in the wild-type controls (*p < 0.05, U-test, Fig. 1a).
However, there was no significant difference in the inci-
dence of CIA (Fig. 1b). To clarify whether the Padi4
gene controls susceptibility to CIA, all immunized mice-
generated circulating anti-CII antibodies were analyzed
by ELISA. The anti-CII IgG and IgM titers in the
wild-type CIA mice sera were compared with those in
the Padi4−/− CIA mice sera. The anti-CII antibody
titers were significantly decreased in the sera of the
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Padi4−/− mice (Fig. 1c, d). With regard to the subsets
of anti-CII IgG, there was no difference in IgG2b and
IgG3 levels on days 35 and 42 (data not shown).
However, anti-CII IgG1 and IgG2a levels were signifi-
cantly lower in the sera of the Padi4−/− mice than in
that of the wild-type mice (Additional file 2).
Expression patterns of the PADI genes
We also investigated the Padi2 and Padi4 expression pat-
terns in the mouse spleen using immunofluorescence
histochemistry (Additional file 3). PAD4+ cells partially
merged with CD3+ T-cells, CD45R (B220) + B-cells, and
Ly-6G+ granulocyte cells, and they primarily merged
with F4/80+ macrophage cells and CD56+ NK cells. In
F4/80+ macrophages, PAD4 was localized to nuclear and
perinuclear locations. PAD2+ cells were also partially
merged with T-cells (CD3+ cells), B-cells [CD45R
(B220) + cells], macrophages (F4/80+ cells), NK cells
(CD56+ cells), and granulocytes (Ly-6G+ cells).
Therefore, PAD2 and PAD4 were widely expressed in
the immune cells. These data were consistent with the
expression pattern in human blood [32, 46]. Padi4
mRNA was highly expressed in granulocytes (Gr-1+
cells) (Fig. 2a, granulocyte); however, PAD4+ cells rarely
merged with granulocytes (Ly-6G+ cells) (Additional file
3). This result contradicts those of previous studies in
human cells [32, 47].
A family of five Padi genes is clustered on chromo-
some 1p35-36 and chromosome 4D3-4E1 in humans
and mice, respectively. To investigate whether the Padi4
gene controls other Padi genes, we performed real-time
RT-PCR Taqman with cells from subsets of Padi4−/−
splenocytes. The mouse Padi4 gene is primarily
expressed in immune cells; thus, we analyzed the expres-
sion patterns of the Padi gene family in T-cells (CD5+
cells), B-cells (CD45R+ cells), macrophages (CD11b +
cells), and dendritic cells (MHC class II+ cells). Padi2
and Padi6 were induced in the absence of the Padi4 gene
Fig. 1 Comparative analyses of Padi4−/− and wild-type mouse models of experimental arthritis. Wild-type (n = 10) and Padi4−/− (n = 7) mice were
immunized with bovine type II collagen (CII) and boosted on day 21 (arrowheads). As control mice, Wild-type (n = 5), and Padi4−/− mice (n = 5)
were immunized with PBS. a Arthritis severity score. The severity of arthritis was graded according to the scale defined in Materials and Methods.
The data are presented as the mean clinical score ± SEM. *P < 0.05 (U-test). b Incidence of arthritis. The percentage of affected animals in each group
was determined on each day. The IgM isotype (c) and IgG isotype (d) of anti-CII antibodies in the wild-type and Padi4−/− mice sera before and after
injection, as determined by ELISA. * P < 0.05, **P < 0.01 (Student’s t-test)
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(Fig. 2b, d), and there was no expression of the
Padi1 gene in cells of both the wild-type and Padi4
−/− mice (data not shown). Padi3 was expressed in
these cells but not in those of the Padi4−/− mice
(Fig. 2c). These data suggested a compensatory effect
among the Padi gene family. In addition, Padi4 was
primarily expressed in granulocytes and macrophages
(Fig. 2a), a finding consistent with those of previous
studies [1, 47]. Furthermore, we isolated and counted
the T-cells (CD3+ cells), B-cells (CD19+ cells), NK
cells (NK1.1+ cells), macrophages (CD11b + cells),
and dendritic cells (MHC class II+ cells) from the
spleens of the wild-type mice and Padi4−/− mice
using FACS. The numbers of these cells were not
significantly different (data not shown).
Padi4 and Padi2 gene expressions corresponding with
CIA treatment
Previously, in RA mouse models, although Padi2 mRNA
was present in the synovium, it was not translated into
the PAD2 protein. In contrast, Padi4 mRNA was absent
in the healthy synovium, but it was readily transcribed
and translated in neutrophils that infiltrated the synovial
tissues during inflammation [48]. To investigate the ef-
fects of PAD4 deficiency, we analyzed the expression
patterns of Padi2 and Padi4 in macrophages (CD11b +
cells) and granulocytes (Ly-6G+ cells) isolated from the
splenocytes of the CIA mice to reveal the relationship
between Padi2 and Padi4. Padi4 mRNA was not
expressed in the macrophages (CD11b + cells) and gran-
ulocytes (Ly-6G+ cells) of the control mice, but it was
induced by CII immunization (Fig. 3a, c). In the wild-
type mice, Padi2 mRNA was not induced by CII
immunization, but it was increased by CII immunization
in macrophages (CD11b + cells) and granulocytes
(Ly-6G+ cells) in the Padi4−/− mice (Fig. 3b, d).
These results suggested that Padi2 gene expression
was compensationally controlled by Padi4 gene
expression.
We investigated PAD2 expression in the PADI4−/− and
wild-type mice by fluorescence immunohistochemistry.
In macrophages (F4/80+ cells) and NK cells (CD56+
cells), PAD2-expressed cells were increased in the
spleens (data not shown). In NK cells, Padi2 RNA had a
higher expression in the Padi4−/− mice than in the wild-
type mice (data not shown). However, Padi4 and Padi2
Fig. 2 Expression of Padi genes in immune cells. Data are obtained from wild-type mice (n = 3) and Padi4−/− mice (n = 3) and are presented as
relative units against GAPDH. a Padi4, b Padi2, c Padi3, and d Padi6. Values represent the means ± standard deviations of data for each sample
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were not induced in NK cells during CII immunization
(Additional file 4). These data suggested that the induc-
tion of Padi2 in NK cells was not related to the develop-
ment of CIA.
CIA in the Padi4−/− mice decreases the production of
inflammatory cytokines
In patients with RA, activated immune cells release
a spectrum of proinflammatory mediators, including
TNF-α, IL-6, and IL-1β, which are responsible for
joint inflammation and destruction [49]. In particu-
lar, TNF-α plays a key pathogenic role. GM-CSF is
secreted by T-cells and macrophages following antigen ac-
tivation, and the function of GM-CSF is indispensable for
the growth and development of macrophages. We per-
formed sandwich ELISA to analyze the CIA serum cyto-
kines in the Padi4−/− mice and wild-type mice. In the
macrophages/monocytes, inflammatory cytokines such as
TNF-α and IL-6 were induced during CIA. TNF-α, IL-6,
and GM-CSF in the sera of the PADI4−/− mice showed
significant decreases at 28 days (Fig. 4a, c, d). There was
no significant difference in IL-1β levels between the
Padi4−/− and wild-type mice (Fig. 4b).
Padi4 is primarily expressed in macrophages/
monocytes and granulocytes in humans, suggesting
that it plays an important role in these cells. In
macrophages/monocytes, many key RA cytokines are
related, e.g., TNF-α, IL-6, IL-1β, IL-10, matrix metallopro-
teinase 9 (MMP9), and GM-CSF. We performed expres-
sion analysis of cytokines in macrophages using real-time
TaqMan RT-PCR assays. In BMMs, the expressions of
TNF-α, IL-6, IL-1β, and GM-CSF were significantly higher
in the wild-type CIA mice than in the Padi4−/− CIA mice
on day 31 (Fig. 5). The expression levels of IL-10 and
MMP9 were not significantly different between the wild-
type and Padi4−/− CIA mice on day 31 (data not
shown). We also evaluated the expression of cytokines
by CD11b + cells. The expression of TNF-α, IL-1β,
Fig. 3 Expression of Padi4 and Padi2 genes in CD11b + and Ly-6G+ cells. Wild-type mice with CIA (n = 19), wild-type control mice (n = 10), Padi4−/−
mice with CIA (n = 17), and Padi4−/− control mice (n = 10) were used. a Padi4 in CD11b + cells, b Padi2 in CD11b + cells, c Padi4 in Ly-6G+ cells, and
d Padi2 in Ly-6G+ cells. Relative units were obtained from the comparative ΔΔCT analysis. Statistical analyses were performed using the Student’s t-test
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MMP9, and GM-CSF in the wild-type mice was in-
creased and that of IL-10, an anti-inflammatory cyto-
kine, was decreased compared with that in the Padi4
−/− mice (Additional file 5).
Localization of citrullinated proteins in synovial tissues in
the CIA mice
In patients with RA, ACPAs react with various citrul-
linated epitopes [50]. The anti-modified citrulline
antibody, which has primarily been used for the de-
tection of citrullinated proteins, indicated that there
are many citrullinated proteins in RA synovial tissues
[51]. However, this antibody cannot identify all syn-
ovial citrullinated proteins that bind ACPAs with high
affinity and specificity. We investigated whether
antigens detected by rabbit anti-CCP antibodies were
present in synovial tissues from the CIA mice and pa-
tients with RA. Antigens detected by anti-CCP anti-
bodies primarily existed in the lining area of the
inflamed synovial tissues from the CIA mice, as
shown in Fig. 6. In human RA synovial tissues, anti-
gens of anti-CCP are located in the sublining area as
well as the lining layer (Fig. 6). The synovial tissues
of some patients with RA had a follicle-like structure
(Fig. 6j, RA1), and CCP antigens were observed in
the marginal zone of the synovial tissue. The patterns
of citrullinated protein localization were the lining
layer, the sublining area, and the extracellular matrix.
Citrullinated fibrinogen is a well-known citrullinated
protein and a candidate RA autoantigen. We investigated
Fig. 4 Cytokine response in wild-type and Padi4−/− mice after collagen-induced arthritis (CIA) treatment. Wild-type (n = 30) and Padi4−/− (n = 24)
mice were challenged with CIA, and serum cytokine protein levels were determined by ELISA on day 28. a tumor necrosis factor alpha (TNF-α),
b interleukin (IL)-1β, c Granulocyte-macrophage colony-stimulating factor (GM-CSF), d IL-6. * P < 0.01, **P < 0.001 (Student’s t-test)
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the distribution of citrullinated fibrinogen in CIA syno-
vium. Citrullinated fibrinogen was observed in the lining
layer and sublining area of the wild-type CIA mice (Fig. 7c,
e, h, j). However, citrullinated fibrinogen was also localized
in the bone marrow cells from both the wild-type and
Padi4−/− CIA mice (Fig. 7d, i).
Discussion
There has been a significant increase in our genetic
understanding of RA because of large-scale GWASs
that have linked common SNPs to RA risk. A large
number of genetic risk factors have been identified in
multiple ethnic groups [9, 52, 53]. These genetic risk
factors identified through GWASs were found to have
modest effect sizes (<1.5). Approximately 30 % of the
identified SNPs as causative variants demonstrate cis-
eQTL; however, the function of some causative SNPs
remains unclear [52].
We previously identified an RA susceptibility variant
within PADI4 in a Japanese population. In the case of
the PADI4 gene, transcripts generated from the suscepti-
bility haplotype were greater than those generated from
the nonsusceptibility haplotype both in vitro and in vivo
[1]. A 1.2-fold change in the transcription of PADI4 was
observed in peripheral blood leukocytes from individuals
with the susceptibility haplotype.
PADI4 produces citrullinated antigens against RA-
specific autoantibodies. However, the pathophysiological
role of PADI4 remains obscure because a relationship
between PADI4 and the development of RA has not
been directly demonstrated. Therefore, it is difficult to
translate the identification of the susceptibility gene into
pathophysiological disease mechanisms.
To reveal the pathophysiological role of the suscepti-
bility genes identified in GWASs, mouse models are
powerful tools that allow testing of the in vivo functions
of genes to better understand the associations between
Fig. 5 Cytokine mRNA expression in bone marrow derived-macrophages. Bone marrow derived-macrophages were obtained from the bone
marrow cells of wild-type (n = 19) and Padi4−/− CIA mice (n = 17) 10 days after booster injection. The cells were then analyzed by real-time
TaqMan RT-PCR for mRNA levels of (a) tumor necrosis factor alpha (TNF-α), b interleukin (IL)-1β, c Granulocyte-macrophage colony-stimulating
factor (GM-CSF), and d IL-6. Relative units were obtained from the comparative ΔΔCT analysis. * P < 0.05, **P < 0.01 (Student’s t-test)
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genes and phenotypes. Some knockout and transgenic
mice show varied phenotypes [54, 55].
In the present study, we investigated the nature of the
role of PADI4 in CIA and the catalytic function of
PADI4 in RA. CIA in the Padi4−/− DBA1J mice was
characterized by a significantly decreased arthritis score.
After 49 days, the Padi4−/− mice displayed an approxi-
mate 50 % disease score compared with the wild-type
Fig. 6 Immunohistochemical localization of antigens detected by anti-CCP antibodies in synovial tissues. Immunohistochemistry with anti-circulated
citrullinated peptide (anti-CCP) antibody (Abbiotec), brown staining of the lining and sublining in the inflamed synovial tissue from
wild-type collagen-induced arthritis (CIA) mice (f and g) and Padi4−/− CIA mice (b and c) and in the synovial tissue from wild-type
control mice (e) and Padi4−/− control mice (a). Staining of a matched irrelevant rabbit IgG-negative control was performed at the same
concentration (d and h). In OA (i) and RA synovial tissue samples (j), CCP antigens were observed in the synovial sublining and lining
layer. Magnification is × 40, except in c, g and j lower (×100)
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mice (Fig. 1). Disease incidence was mildly decreased, al-
beit not significantly (Fig. 1). The average rate of de-
crease in the disease scores was approximately 25 %
(data not shown). Therefore, we found that the Padi4−/−
mice showed decreased RA disease scores, consistent
with results of the eQTL study by Suzuki et al. [1], and
the population attributable risk based on data from their
study [1] can be calculated as 24 %. Previously, Rohr-
bach et al. performed serum-transfer arthritis model
with PAD4 KO mice with B6 WT, but there were no
statistical significant differences in clinical scores, swell-
ing, joint erosion or joint invasion. In our study, CIA
model in B6 strain, there were no statistical significant
differences in arthritis scores and was consistent with
the previous study. We consider that MHC class II mol-
ecule in each strain has a different potential role for
autoimmunity [56].
Anti-CII antibodies have been recognized as important
pathogenic factors for the development of CIA in mice.
In the CIA mice, the Padi4 gene affected the production
of anti-CII IgM and IgG (Fig. 2), particularly IgG1 and
IgG2a (Additional file 2). The association between
elevated IgG2a levels and the occurrence of arthritis in-
dicates the pathogenic role played by Th1 cells and the
Fig. 7 Immunohistochemical localization of citrullinated fibrinogen in synovial tissues of collagen-induced arthritis (CIA) mice. Immunohistochemistry
using anti-citrullinated fibrinogen antibody (ModiQuest) and DAB staining of the lining and sublining in an inflamed synovial tissue from wild-type CIA
mice (n = 3, the scores are 4, c–e) and Padi4−/− CIA mice (n = 3, the scores are 4, h–j) and in a synovial tissue from wild-type control mice (n = 1, a) and
Padi4−/− control mice (n = 1, f). Staining of a matched irrelevant rabbit IgG-negative control performed at the same concentration (b and g). (a–c, f–h)
Magnification, ×40. (d, e, i, j) Magnification, ×100
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beneficial role played by Th2 cells [57]. Inflammation in
CIA is highly dependent on a predominantly Th1 re-
sponse, which is characterized by the presence of anti-
collagen IgG2a antibodies and the proinflammatory
cytokine TNFα. In the Padi4−/− CIA mice sera, anti-CII
IgG2a was decreased, suggesting that the deficiency of
PAD4 led to the inhibition of Th1-mediated inflamma-
tion. This subclass distribution was characteristic of T-
cell-dependent antibody production and suggested HLA
involvement. These findings may be relevant to the gen-
etic relationship between PADI4 and HLA [16, 58]. The
reduction of anti-CII IgM also suggested that Padi4 also
have pathologically effect on antigen-specific B cells.
In addition, we measured anti-CCP IgG antibodies
using MESACUP ELISA with the CIA mice sera. How-
ever, the titers of anti-CCP IgG in the Padi 4−/− CIA
mice sera were mildly decreased but not significantly dif-
ferent from those in the wild-type CIA mice sera (data
not shown). We also confirmed that citrullinated pep-
tides reacted with CIA sera in the Padi4−/− mice [23, 50,
59, 60]. These data also suggested that the Padi4 gene is
compensated for by other Padi gene family members.
We analyzed the expression patterns of the Padi gene
family in immune cells isolated from the splenocytes of
the wild-type and Padi4−/− mice. In the Padi4−/− mice,
the expressions of Padi2 and Padi6 were increased.
These data suggested that the deficiency of Padi4 was
functionally complemented by Padi2 and Padi6 (Fig. 3).
PAD4 only has a nuclear localization signal and the
ability to modify histones. It can directly control tran-
scription via histone methylation and citrullination [61].
It is indicated that PADI4 may control the transcription
of Padi2 and Padi6. We speculated that the function of
Padi4 is important for gene expression via histone
citrullination as well as the production of citrullinated
autoantigens.
To investigate the function of the Padi4 gene in auto-
antigen production, we examined the effects of Padi4 on
serum cytokine levels. The proinflammatory cytokines
TNF-α, IL-1β, and IL-6 were increased at the protein
level in the sera of the early-onset CIA mice (Figs. 4, 5).
The decrease in the protein levels of Il-1β was not sig-
nificant whereas those of TNF-α and IL-6 were signifi-
cantly decreased in the Padi4−/− mice. Moreover, the
mRNA levels of these cytokines in the macrophage-
derived bone marrow from the Padi4−/− CIA mice were
also significantly decreased compared with those in the
macrophage-derived bone marrow from the wild-type
CIA mice.
GM-CSF also plays a proinflammatory role that has
been demonstrated in various models of inflammation
and immunity [62]. GM-CSF-deficient mice show de-
creased susceptibility to CIA; furthermore, anti-GM-CSF
is a candidate drug for autoimmune diseases. The
protein levels of GM-CSF in sera in the Padi4−/− CIA
mice were decreased compared with those in the wild-
type CIA mice (Fig. 4, 5). Therefore, Padi4 is involved in
inflammation in CIA via effects on proinflammatory cy-
tokines. IL-10 is one of the anti-inflammatory cytokines,
and it inhibits the secretion of IL-1β, TNF-α, and IL-6
from macrophages. The expression level of IL-10 in the
CD11b +macrophages in the Padi4−/− CIA mice was de-
creased compared with that in the wild-type CIA mice
(Additional file 5).
In a previous report, PAD4 and citrullinated proteins
were not detectable before the clinical signs of arthritis;
rather, citrullinated proteins and PAD4 increased as the
inflammation progressed [63]. These data suggested that
PAD4 and citrullinated proteins played important roles
in RA development. Although PAD4 has a nuclear
localization signal, it is also present in the cytoplasm of
infiltrating mononuclear cells [64]. To investigate the
localization of citrullinated proteins in the synovial tis-
sues, we performed immunohistochemistry with rabbit
anti-CCP antibodies. Antigens recognized by anti-CCP
antibodies were observed in joints from both the Padi4
−/− and wild-type mice. The antigens were also detected
in the lining and sublining areas of proliferated synovial
tissues from the wild-type and Padi4−/− CIA mice (Fig. 6).
The localization of citrullinated fibrinogen in the syn-
ovial tissue exhibited the same pattern as the CCP anti-
gens. We speculated that expressed PAD4 in synovial
tissues or synovial fluids play an important role in the
supply of citrullinated antigens; however, other PADs
should also be involved in the citrullination.
PAD4 regulates transcription via histone methylation.
We investigated the effects of PAD4 on the transcrip-
tional pattern of macrophages from the Padi4−/− mice
and identified the Fus gene, which was regulated by
PAD4 (data not shown). The Fus gene is known as an
ALS-related gene and has been implicated in the patho-
genesis of myxoid liposarcoma and low-grade fibromyx-
oid sarcoma [65, 66]. FUS is a member of the TET
family and is involved in transcriptional activation. The
FUS gene is highly expressed in immune cells such as
T-cells, B-cells, monocytes, and NK cells. FUS is a
kind of RNA-binding protein and regulated by tran-
scription factor Sp1, GCF, and AP-1. Additionally, our
data suggested that Padi4 regulated Fus gene via
citrullination of the histone H3. In this study, we also
suggested that pathway by which Padi4 and Fus
regulate pro-inflammatory cytokines. FUS gene is
well-known as related-gene of tumor of human myx-
oid liposarcoma and associated with amyotrophic lat-
eral sclerosis. However, the pathological function of
Fus gene on immune system is not clear.
Recently, it was reported that PADs have various
relationships with some diseases such as RA, cancer,
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Alzheimer’s disease, psoriasis, and colitis [36, 41, 46,
67–69]. The deimination of the PAD substrates may
be related with TNF-α signaling. Actually, Shelef et al., in-
dicated that TNF-a induced arthritis had lower levels of
autoantibodies using TNF-a-overexpressing and PAD4 de-
ficient mice [70]. Anti-TNF-α monoclonal antibodies are a
common treatment for autoimmune diseases (i.e., RA and
IBD), suggesting that dysregulated PADs cause uncon-
trolled TNF-α signaling.
Therefore, PAD enzymes can be novel candidates for
the development of a therapy that targets these diseases.
Cl-amidine is a bioavailable haloacetamidine-based pan
inhibitor that inhibits inflammation in the murine CIA
model of RA [40]. It was also reported that Cl-amidine sup-
pressed colitis and breast cancer [41, 69]. However, we could
not replicate the inhibition of CIA by Cl-amidine (data not
shown). In summary, we demonstrated that PADI4 plays a
role in RA progression. Our observations and previous data
have indicated that a potential role for dysregulation (i.e., in-
crement) of PAD activity is related to the onset and progres-
sion of various diseases, including RA.
Conclusions
The Padi4 gene, which was identified by large scale
multi-ethnic RA GWAS, is functionally related to the
RA model mice. In model mice, Padi4 had an effect on
arthritis scores but not on the rate of onset. Padi4 had
the ability to provide citrullinated antigens and tran-
scriptionally control genes, e.g., inflammatory cytokines.
Consequently, inhibitors of PAD4 are good target gene
for drug development because there is no physiological
abnormality with or without Padi4.
Additional files
Additional file 1: Generation of a Padi4−/− mouse. (a) Genomic structure
of A Padi4−/− mouse. A 5837-bp fragment containing exon 1 and intron 1
of Padi4 was inserted to the targeting vector. We constructed the targeting
vector to replace exon 1 and intron 1, including the transcription initiation
site, using mouse PGK-1 promoter and the neomycin-resistance gene. We
confirmed the knockout condition by Southern blotting (b) and RT-PCR (c).
(d) Distributions of immune cells in the spleen of wild-type (n = 3) and
Padi4−/− (n = 3) mice were analyzed by FACS. (e) Hematoxylin and eosin
(HE) staining of Padi4-expressed tissues from the wild-type (WT) mouse,
Padi4+/− (Heterozygote) mouse, and Padi4−/− (KO) mouse. (PDF 458 KB)
Additional file 2: Serum anti-CII antibodies in CIA using Wild type and
Padi4−/− mice. Anti-CII IgG1 antibodies (a) and IgG2a antibodies (b) in
the sera of 31 Wild type CIA mice, 14 Wild type control mice, 28 Padi4
−/− CIA mice, and 14 Padi4−/– control mice at day 35 after collagen
injection. *P < 0.01 (Student’s t-test). (TIF 292 KB)
Additional file 3: Padi2 and Padi4 are expressed in the spleens of wild-
type mice. (a–e) Immunofluorescence staining (×40) shows that Padi2 is
expressed ubiquitously in the spleen. Spleens were probed with anti-Padi2
(green fluorescent signal) and cell surface markers (red fluorescence signal;
a, CD3; b, B220; c, Gr-1; d, CD56; e, F4/80). The nuclei were stained with DAPI
(blue fluorescence signal). The arrows indicate the colocalization of Padi2
and each cell surface marker. (f–k) Immunofluorescence staining (×40)
shows that Padi4 was expressed in splenocytes. The spleens were probed
with anti-Padi4 (green fluorescence signal), and cell surface markers (red
fluorescence signal; f, CD3; g, B220; h, Gr-1; i, CD56; j, F4/80). Nuclei were
stained with DAPI (blue fluorescence signal). (K) Immunofluorescence staining
(left, ×40; right, ×280) shows that Padi4 was localized in both the nuclei and
cytoplasm of macrophages, which expressed F4/80. (PDF 286 KB)
Additional file 4: Padi2 and Padi4 expression in NK1.1+ cells. mRNA
levels were determined by real-time TaqMan RT-PCR using NK1.1+ cells as
a reference for GAPDH normalization. Padi2 and Padi4 mRNA expressions
were not different between wild-type collagen-induced arthritis (CIA)
(n = 10) and control (n = 8) mice spleens. (PDF 209 KB)
Additional file 5: Cytokine mRNA expression in CD11b +macrophages
in the spleen. CD11b + wild-type (n = 19) and Padi4−/− CIA mice (n = 17)
were used for 10 days from the day after booster injection. The cells
were analyzed by real-time TaqMan RT-PCR for mRNA levels of (a) tumor
necrosis factor alpha (TNF-α), (b) CSF-2, (c) IL-1β, (d) IL-6, and (e) IL-10.
*P < 0.05, **P < 0.01 (Student’s t-test). (PDF 173 KB)
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